PeptideGlobal

Wegovy generic in Korea moves toward a 2028 launch as Korea United Pharm plans a first trial

Korea United Pharm plans a bioequivalence study of its semaglutide copy UI112 against Wegovy in 44 healthy adults during 2027, aiming to launch in 2028 when the Korean patent is expected to end, Health Korea News reports.

Illustration for the story: Wegovy generic in Korea moves toward a 2028 launch as Korea United Pharm plans a first trial

Illustration by Peptide Global, not a picture of the place in the story.

The short of itKorea United Pharm plans a 2027 bioequivalence study of its semaglutide copy UI112 against Wegovy and targets a Korean launch in 2028.

A Wegovy generic in Korea is now part of Korea United Pharm's plans, with a bioequivalence study of its candidate UI112 set to start in January 2027 and a launch targeted for 2028, Health Korea News reported on 16 November. The timing follows the expected end of the Korean semaglutide patent in 2028. The study will compare UI112 with Novo Nordisk's pen in healthy adults at Chungbuk National University Hospital. The report carried no comment from the company on price, partners or manufacturing.

The UI112 study design

According to the Health Korea News article, the Phase 1 study will enrol 44 healthy adults and run from January to December 2027. It is randomised and open label, uses a single injection of each product, and follows a two period, two sequence crossover design. Half the volunteers, 22 people, receive Wegovy first and UI112 second, while the other half receive them in reverse order, with a six week washout between injections. Blood samples are taken for up to 504 hours after each injection to track semaglutide levels. The long sampling window reflects how slowly semaglutide leaves the body, which is also why the drug can be given once a week.

The main measures are AUCt, the total drug exposure up to the last measurable point, and Cmax, the peak blood level. UI112 will count as bioequivalent if the 90% confidence interval of the ratio between the two products falls between 80.00% and 125.00% for both measures, the standard range used by regulators. Secondary measures include exposure up to 168 hours, exposure extrapolated to infinity, the time to peak and the half life. Safety checks cover adverse events, vital signs, heart tracings, laboratory tests and blood sugar. For a peptide copy, the manufacturing process and the impurity profile are usually examined alongside these blood level data before any approval.

Why 2028 matters for a Wegovy generic in Korea

Novo Nordisk's semaglutide patent in Korea is expected to expire in 2028, the report said, and Korea United Pharm has set its launch target for the same year. Wegovy reached Korean clinics in October 2024 and recorded cumulative sales of 762.6 billion won through the second quarter of this year, according to IQVIA figures cited by Health Korea News. That makes it one of the largest new drug markets in the country. Prices are already under strain, as our report on Korean obesity drug prices showed, after a new rule let patients bring home pens prescribed and bought abroad. A domestic copy would add pressure from inside the market.

Wegovy reached Korean clinics in October 2024 and recorded cumulative sales of 762.6 billion won through the second quarter of this year, according to IQVIA figures cited by Health Korea News.

Domestic competition is also coming from other directions. Hanmi Pharmaceutical's efpeglenatide pen reached selected Korean clinics in October with a lower starting price than Mounjaro, as we reported on the Hanmi Epe launch. Samchundang Pharm is developing a copy of Rybelsus, Novo Nordisk's oral semaglutide for diabetes, rather than an obesity product, the report noted. A Wegovy generic in Korea from 2028 would bring a different kind of pressure on the brand: a copy of the same molecule, which doctors could switch patients to without learning a new drug. How much cheaper it would be is unknown, because the company has given no price target.

ItemDetail
CompanyKorea United Pharm
CandidateUI112, a semaglutide copy of Wegovy
StudyPhase 1 bioequivalence, randomised, open label, crossover
SiteChungbuk National University Hospital
Volunteers44 healthy adults
Planned datesJanuary to December 2027
Launch target2028
Korean patent endExpected in 2028
Wegovy sales in Korea762.6 billion won to the second quarter of 2026, IQVIA

How other markets went first

Korea comes late in the semaglutide generic cycle. Canada's patent lapsed first, in January, and India, China and Brazil followed in March, according to the dates listed by Health Korea News. In India, Dr Reddy's, Zydus and Sun Pharma launched products after the March expiry, with Sun selling separate brands for obesity and for type 2 diabetes. Canada has approved copies of both Ozempic and Wegovy, including Apotex's Wegovy copy Sevmia, cleared on 29 June, which Apotex has said it plans to launch by the end of the year. Our semaglutide patent expiry map traced the same uneven pattern across markets in October.

China shows that patent expiry alone does not open a market. The patent there lapsed in March, but no generic has launched, because Novo Nordisk holds its Chinese approval through its Swiss company, and data protection under the free trade agreement between China and Switzerland runs until April 2027, the report said. It did not say whether later Korean patents on formulations or pens could affect the timing of copies in Korea. In the United States the main patent is expected to run until 2032, and in the European Union and Japan until 2033. That leaves Korea among the earlier wealthy markets to open, which matters for companies planning to sell semaglutide copies across Asia.

What to watch next

The first marker is regulatory clearance of the study protocol and the January start at Chungbuk National University Hospital. The second is the result. If UI112 meets the bioequivalence range, Korea United Pharm can build a filing to the Ministry of Food and Drug Safety. The third is manufacturing. The report did not say where the semaglutide ingredient will come from or who will fill the pens, details that matter after other generic makers ran into supply and impurity problems this year. A company that can show a reliable source will be better placed when the patent ends, because pharmacies and clinics would need stock from the first day of the generic market.

The fourth marker is the response from Novo Nordisk, which the report did not cover. Rival Korean makers may also reveal their own Wegovy generic in Korea programmes now that one company has moved, although none was named. For patients the change is still years away. Until a copy is approved, the market will rely on branded pens, Hanmi's domestic product and pens bought abroad under the new carry in rule. Korea United Pharm's plan shows that local firms are now preparing for the end of exclusivity rather than waiting for it, and the clinical study next year will be the first real test of whether the 2028 target holds.

Conclusion

Korea United Pharm plans to test UI112 against Wegovy in 44 healthy adults during 2027 and targets a launch in 2028, when the Korean semaglutide patent is expected to end. A Wegovy generic in Korea would enter a market already under price pressure. Watch the study start, the bioequivalence result, the ingredient source and the response from Novo Nordisk.

Why it matters in South Korea

Wegovy has sold 762.6 billion won in Korea since its October 2024 launch, and its Korean patent is expected to end in 2028. A local copy of the same molecule could bring the first generic price competition to the market.

What to watch

The January 2027 study start at Chungbuk National University Hospital, the bioequivalence result, the ingredient source and any rival Korean Wegovy generic programmes.

Sources

  1. Health Korea News: Korea United Pharm pursues Wegovy generic development

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.